ARCHIVEHow Slingshot Biosciences Used Humor to Win Over Flow Cytometry Labs
Slingshot Biosciences' "Time to Take Control" is a 2023 film campaign created by Chicago-based agency Umault, targeting pharmaceutical researchers and flow cytometry laboratory professionals across the United States with a humor-driven argument for the company's on-demand cellular controls and cell lines.
Slingshot Biosciences manufactures on-demand cellular controls and cell lines for flow cytometry. The Emeryville, California-based biotechnology company occupies a specialised niche within pharmaceutical and life science research, supplying the reference materials that scientists depend on to validate data from cellular analysis instruments. The campaign was published in the United States in February 2023 and comprises a single film asset. Its title, "Time to Take Control," operates simultaneously as a product promise and a motivational challenge directed at researchers who understand the professional cost of unreliable experimental variables.
The campaign's strategic objective is to position Slingshot Biosciences as the dependable alternative to improvised, inconsistent laboratory controls. Rather than leading with technical specification, Umault's creative approach frames the message around the frustrations of scientific uncertainty, using comic visual metaphors — lucky charms, crossed fingers, knocking on wood — to illustrate what happens when researchers rely on anything less than a validated, on-demand cellular control. The tone deliberately contrasts the absurdity of superstition with the precision that flow cytometry demands, making the product's value proposition land as relief rather than advertisement. In the United States, where pharmaceutical R&D investment drives sustained demand for reproducible laboratory tools, the campaign speaks directly to a professional audience that rarely encounters advertising calibrated to its specific anxieties. The Clapboard Score for "Time to Take Control" is 60 out of 100, reflecting a campaign that executes its niche creative strategy with clarity but operates within the inherent reach constraints of a highly specialised B2B sector.
ARCHIVEUmault identified a core tension inside every flow cytometry laboratory in the United States. The scientific community that operates these instruments is acutely aware that the quality of cellular controls determines the credibility of every downstream result, yet that same community is chronically underserved by marketing that speaks its language. The strategic insight driving "Time to Take Control" is that researchers do not need to be educated about why controls matter; they need to be shown that Slingshot Biosciences understands the professional stakes of getting them wrong.
The global flow cytometry market was estimated at approximately 4.9 billion to 5.2 billion dollars in 2023, according to DelveInsight and BCC Research respectively, with compound annual growth rates projected between 7.5 and 8.3 percent through the late 2020s. In the United States, the pharmaceutical and life science research sector represents the largest geographic concentration of flow cytometry demand, anchored by academic medical centres, contract research organisations, and biopharma R&D divisions. Within that landscape, Slingshot Biosciences competes against established instrument and reagent suppliers including BD Becton Dickinson, which holds an estimated 24 to 28 percent global flow cytometry market share according to growth market reports compiled by industry analysts at GrowthMarketReports.com, and Thermo Fisher Scientific, which maintains a broad portfolio of cellular analysis reagents and reference standards. Both competitors command significant brand recognition among laboratory buyers, which makes differentiation through creative communication more strategically valuable for a growth-stage company like Slingshot Biosciences.
Umault's decision to pursue comedy as the primary creative register is itself a market strategy. As noted in Umault's own published case work at umault.com, the agency specialises in B2B video content that rejects the conventions of corporate explainer filmmaking in favour of emotional and narrative approaches. In a category where most competitive advertising defaults to data sheets and instrument demonstrations, a campaign built around superstition as a foil for scientific reliability occupies uncontested creative territory. That positioning choice is as much a media strategy as a messaging one: memorable creative travels further on limited budgets, and in a specialised United States research market where word-of-mouth among laboratory professionals carries significant weight, shareability has direct commercial value.
Creative director Guy Bauer of Umault led the campaign, with Ted Holmwood serving as director of photography and Jen Bauer as producer. Hope Morley served as agency producer, with additional crew contributions from Gadi Solis, Emmanuel Terrell, and Torie Conn. The production team's collective task was to translate a highly technical product proposition into a piece of film that a pharmaceutical researcher would find both credible and genuinely entertaining — a creative brief that demands precise tonal calibration.
The film deploys lucky charms, crossed fingers, and knocking on wood as its central comic devices. Each of these gestures is universally legible as superstition, which makes them immediately funny in a laboratory context where scientific method is the professional identity of the audience. The joke is not at the researcher's expense; it is directed at the conditions that force researchers to work with inadequate controls, implicitly casting Slingshot Biosciences as the rational solution to an irrational situation. This distinction matters because B2B healthcare advertising that patronises its audience tends to generate resistance rather than engagement, particularly among scientists who evaluate claims critically by professional habit.
The production is a single film asset, which concentrates the entire creative argument into one piece of content rather than dispersing it across a campaign ecosystem. That structural choice reflects a resource-conscious approach to B2B filmmaking that Umault has described as central to its methodology at umault.com: invest in a single strong idea executed well rather than a diffuse multi-asset campaign executed adequately. Ted Holmwood's cinematography supports the tonal contrast at the heart of the script, grounding the comedic moments in a recognisable laboratory visual language that signals authenticity to a scientifically literate audience. The result is a piece of pharmaceutical advertising that works precisely because it does not look or feel like pharmaceutical advertising, earning attention in the United States research community through surprise rather than repetition.
Slingshot Biosciences recorded a campaign engagement rate of 77.81 percent following the launch of "Time to Take Control," compared to the brand's prior average engagement rate of 30 percent, as reported by Marsha Hartman, SVP Sales and Marketing at Slingshot Biosciences. Web traffic to the Slingshot Biosciences site tripled following the campaign launch, according to the same source. Hartman stated at umault.com that the campaign "set marketing records" and that Umault "delivered on time" while remaining "open to feedback" throughout the production process.
No independently verified third-party performance data for the campaign — including sales lift, revenue impact, lead generation metrics, or market share change — is publicly available. The figures cited above originate from Slingshot Biosciences' own published commentary and should be read in that context. No awards have been verified for "Time to Take Control" at Cannes Lions, the Effies, The One Show, D&AD, the Clios, the Webby Awards, or WARC Awards.
The campaign archive recorded 3,113 views, 13 likes, and zero comments at the time of the archive snapshot. These platform-level figures reflect the narrow distribution footprint appropriate for a campaign targeting a specialised professional audience in the United States rather than a mass consumer market. Structural effectiveness analysis supports a positive reading: the creative strategy of using humour to address a genuine professional pain point is well matched to the audience's decision-making psychology, and a near-tripling of baseline engagement rate suggests the film reached its intended viewers with unusual efficiency. For a growth-stage biotechnology company competing against entrenched players including BD Becton Dickinson and Thermo Fisher Scientific in the United States flow cytometry market, that kind of qualified audience response carries disproportionate commercial value relative to raw view counts.
"Time to Take Control" is a 2023 film campaign created by Umault for Slingshot Biosciences. It targets pharmaceutical researchers and flow cytometry laboratory professionals in the United States, using humour built around superstitious lab behaviour to position Slingshot's on-demand cellular controls as the reliable, scientifically rigorous alternative.
Umault produced the campaign. Creative director Guy Bauer led the project, with Ted Holmwood as director of photography, Jen Bauer as producer, and Hope Morley as agency producer. Additional crew included Gadi Solis, Emmanuel Terrell, and Torie Conn. The campaign was published in the United States in February 2023.
Slingshot Biosciences reported a campaign engagement rate of 77.81 percent, more than double the brand's prior 30 percent average, according to SVP Marsha Hartman. Web traffic tripled following launch. No independently verified third-party metrics are publicly available, but the client described the results as setting internal marketing records.
Umault identified that flow cytometry researchers in the United States are underserved by conventional technical advertising. Using superstition — lucky charms, crossed fingers, knocking on wood — as a comic foil for unreliable lab controls made the product's value proposition memorable and emotionally resonant without patronising a scientifically literate professional audience.
Slingshot Biosciences manufactures on-demand cellular controls and cell lines for flow cytometry. Based in the United States, the company supplies pharmaceutical and life science researchers with validated reference materials used to ensure the accuracy and reproducibility of cellular analysis data in drug discovery and development workflows.
"Time to Take Control" by Slingshot Biosciences received a Clapboard Score of 60 out of 100. The score reflects clear and competent execution of a niche B2B creative strategy, acknowledging that the campaign's reach is structurally constrained by its highly specialised target audience within the United States pharmaceutical research sector.
.webp)
Creative Collaboration Platform: The Backbone of Modern Creative WorkWhat is a creative collaboration platform?Clapboard defines a creative collaboration platform as the operational core for today’s distributed creative teams. This is not a collection of digital collaboration tools stitched together; Clapboard’s system
Understanding the Creative Production MarketplaceWhat is a Creative Production Marketplace?Clapboard defines a creative production marketplace as a structured ecosystem where brands, agencies, and production talent converge to execute video, advertising, and branded content at scale. Unlike the legacy agency or freelanREAD FULL ARTICLE
The Urgent Need for a Creative Production Operating SystemWhy Traditional Creative Production Models Break DownClapboard sees the creative production landscape shifting under pressure. Content velocity is no longer a buzzword—it’s a mandate. Modern advertising demands relentless output across dozens of channels, each wREAD FULL ARTICLE
.jpg&w=256&q=75)
